文献速递肝病消化道肿瘤与早癌

液体活检在肝细胞癌检测、预后判断和疾病监测中的效用:系统综述

Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-11

该系统综述纳入112项原始研究,评估液体活检(CTC、cfDNA、细胞外囊泡)用于肝细胞癌检测、预后判断和治疗监测的价值。cfDNA联合AFP检测肝癌比单用AFP更准确;术前CTC检测与切除后复发相关(14项研究中13项);治疗前后CTC数量变化比单用治疗前计数更能识别复发;cfDNA可早于影像学发现复发或进展。但研究存在偏倚风险,需标准化后方可评估临床效用。

要点

  • cfDNA联合AFP检测肝癌比单用AFP更准确。
  • 术前CTC检测与肝癌切除后复发相关(14项研究中13项)。
  • cfDNA可早于影像学发现肝癌复发或进展。

核心结论

  • CTC和cfDNA检测可能有助于判断肝癌患者预后和监测疾病,cfDNA检测可能有助于肝癌检测,但研究存在偏倚风险。
  • 在评估液体活检对肝癌检测和管理的临床效用前,研究必须标准化。

研究设计与样本

  • 系统综述纳入2019年12月1日前发表的原始研究,最终分析112项研究:67项关于检测、46项关于预后判断、25项关于治疗监测或选择。

主要发现

  • 6项研究评估细胞外囊泡检测、2项研究评估CTC检测肝癌,多数研究发现CTC或细胞外囊泡联合AFP比单用AFP更准确识别肝癌患者。
  • 14项研究中13项显示术前CTC检测与肝癌切除后复发相关;cfDNA和细胞外囊泡作为预后因素研究较少。
  • 治疗前后CTC数量变化比单用治疗前计数更能准确识别肝癌复发;cfDNA检测可早于影像学发现疾病复发或进展。
  • 几乎没有证据表明液体活检分析有助于肝癌治疗选择;质量评估显示肝癌检测和预后判断研究存在偏倚风险。

临床怎么用

  • cfDNA联合AFP可能提高肝癌检测准确性,但需研究标准化后方可常规应用。
  • 术前CTC检测可能有助于评估肝癌切除后复发风险。
  • 治疗前后CTC数量变化和cfDNA检测可能有助于监测复发或进展,可能早于影像学。

局限性

  • 研究存在偏倚风险,尤其在肝癌检测和预后判断方面。
  • 液体活检分析方法尚未标准化,限制临床效用评估。
  • cfDNA和细胞外囊泡作为预后因素的研究较少。
  • 几乎没有证据支持液体活检用于肝癌治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liquid biopsies, or blood samples, can be analyzed to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles, which might identify patients with hepatocellular carcinoma (HCC) or help determine their prognoses. We performed a systematic review of studies of analyses of liquid biopsies from patients with HCC and their comparisons with other biomarkers. METHODS: We performed a systematic review of original studies published before December 1, 2019. We included studies that compared liquid biopsies alone and in combination with other biomarkers for the detection of HCC, performed multivariate analyses of the accuracy of liquid biopsy analysis in determining patient prognoses, or evaluated the utility of liquid biopsy analysis in monitoring treatment response. RESULTS: Our final analysis included 112 studies: 67 on detection, 46 on determining prognosis, and 25 on treatment monitoring or selection. Ten studies evaluated assays that characterized cfDNA for detection of HCC in combination with measurement of α-fetoprotein (AFP)-these studies found that the combined measurement of cfDNA and AFP more accurately identified patients with HCC than measurement of AFP alone. Six studies evaluated assays for extracellular vesicles and 2 studies evaluated assays for CTC in detection of HCC, with and without other biomarkers-most of these studies found that detection of CTCs or extracellular vesicles with AFP more accurately identified patients with HCC than measurement of AFP alone. Detection of CTCs before surgery was associated with HCC recurrence after resection in 13 of 14 studies; cfDNA and extracellular vesicles have been studied less frequently as prognostic factors. Changes in CTC numbers before vs after treatment more accurately identify patients with HCC recurrence than pretreatment counts alone, and measurements of cfDNA can identify patients with disease recurrence or progression before changes can be detected by imaging. We found little evidence that analyses of liquid biopsies can aid in the selection of treatment for HCC. Quality assessment showed risk of bias in studies of HCC detection and determination of prognosis. CONCLUSIONS: In a systematic review of 112 studies of the accuracy of liquid biopsy analysis, we found that assays for CTCs and cfDNA might aid in determining patient prognoses and monitoring HCC, and assays for cfDNA might aid in HCC detection, but there is a risk of bias in these studies. Studies must be standardized before we can assess the clinical utility of liquid biopsy analysis in the detection and management of patients with HCC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chen VL, Xu D, Wicha MS, et al. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. Clin Gastroenterol Hepatol. 2020. PMID: 32289533. doi:10.1016/j.cgh.2020.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。